Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Cash from Financing Activities (2016 - 2025)

iBio (IBIO) has disclosed Cash from Financing Activities for 14 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 5879.61% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.7 million through Dec 2025, up 265.66% year-over-year, with the annual reading at $8.9 million for FY2025, 63.55% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $8.8 million at iBio, down from $46.7 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $46.7 million in Q3 2025, with the low at -$6.0 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $4.6 million, with a median of $2.0 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities crashed 117.15% in 2021, then soared 28930.25% in 2025.
  • Over 5 years, Cash from Financing Activities stood at -$6.0 million in 2021, then soared by 49.41% to -$3.0 million in 2022, then surged by 231.57% to $4.0 million in 2023, then crashed by 103.8% to -$152000.0 in 2024, then surged by 5879.61% to $8.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $8.8 million, $46.7 million, and $8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.